Oncolytic Immunotherapy: Where Are We Clinically?
Open Access
- 16 January 2014
- journal article
- review article
- Published by Hindawi Limited in Scientifica
- Vol. 2014, 1-7
Abstract
Following a century of preclinical and clinical work, oncolytic viruses are now proving themselves in randomized phase 3 trials. Interestingly, human data indicates that these agents have potent immunostimulatory activity, raising the possibility that the key consequence of oncolysis might be induction of antitumor immunity, especially in the context of viruses harboring immunostimulatory transgenes. While safety and efficacy of many types of oncolytic viruses, including adenovirus, herpes, reo, and vaccinia seem promising, few mechanisms of action studies have been performed with human substrates. Thus, the relative contribution of “pure” oncolysis, the immune response resulting from oncolysis, and the added benefit of adding a transgene remain poorly understood. Here, the available clinical data on oncolytic viruses is reviewed, with emphasis on immunological aspects.Keywords
This publication has 71 references indexed in Scilit:
- Resistance to Oncolytic Myxoma Virus Therapy in Nf1−/−/Trp53−/− Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I InterferonPLOS ONE, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic AdenovirusMolecular Therapy, 2011
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic AdenovirusMolecular Therapy, 2011
- Feasibility of Adenovirus-Mediated hNIS Gene Transfer and 131I Radioiodine Therapy as a Definitive Treatment for Localized Prostate CancerMolecular Therapy, 2011
- Sodium Iodide Symporter SPECT Imaging of a Patient Treated With Oncolytic Adenovirus Ad5/3-Δ24-hNISMolecular Therapy, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14Nature Medicine, 2010
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSFMolecular Therapy, 2010